glp 1 for diabetes type 2 GLP-1 receptor agonists are increasingly used to treat and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal GLP1 Receptor Agonists vs SGLT2-I

10.3389/fnmol.2021.697440 Front

doi: 10.1111/dom.13494 81 JungSYKimJSChoiIYLeeGHKimYHKangJHet al

2013;8(1):e49286

When Ozempic (semaglutide) was approved by the FDA in 2017, doctors quickly realized that diabetic patients who took the drug also lost weight

Watch for: Unusual injection site reactions (excessive redness, swelling, pain, or injection site reactions beyond normal ) Gastrointestinal symptoms that seem disproportionate to your dose ( unexpected diarrhea , severe nausea, headaches ) Signs of inadequate blood sugar control (for diabetes patients) Allergic-type reactions (hives, difficulty breathing, rapid heartbeat) Most people who use recently expired tirzepatide experience nothing more than slightly reduced effectiveness